A Prospective, Cohort Study of Renal and Bone Outcome After Changing Tenofovir in Patients With Renal Toxicity According to Antiretroviral Strategy

Trial Profile

A Prospective, Cohort Study of Renal and Bone Outcome After Changing Tenofovir in Patients With Renal Toxicity According to Antiretroviral Strategy

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2016

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Mar 2016 New trial record
    • 09 Mar 2016 Results (n=228) published in the JAIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top